Copyright © Inderes 2011 - present. All rights reserved.
Logga in för att få aviseringar
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • inderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Följda bolag
    • Teamet
Pressmeddelande

Revenio Group’s Financial statement release 2024 will be published on February 13, 2025

2025-01-29 08:00
Revenio Group

Revenio Group Corporation | Press Release | January 29, 2025 at 09:00:00 EET

Revenio Group Corporation’s Financial statement release 2024 will be published on Thursday, February 13, 2025, approximately at 09.00 a.m. (EET). The release will be available at www.reveniogroup.fi/en/investors/reports_and_presentations.

A live webcast and teleconference call for analysts, investors, and media will be held in English at 3.30 p.m. (EET) on February 13, 2025 at Sanomatalo, Flik Studio Eliel, Töölönlahdenkatu 2, Helsinki. CEO Jouni Toijala and CFO Robin Pulkkinen will present the Financial statement release.

The webcast can be watched live at: https://revenio.events.inderes.com/q4-2024

Participants attending the event in person are requested to register in advance. Please send your registration by February 11, 2025, by email to ir@revenio.fi.

To ask questions, please join the teleconference by registering using the following link: https://events.inderes.com/revenio/q4-2024/dial-in
Phone numbers and the conference ID to access the conference will be provided after registration. To ask a question, please press #5 on your telephone keypad to enter the queue.

A recording of the webcast will be published on www.reveniogroup.fi/en/ after the event.

For further information, please contact
Robin Pulkkinen, CFO, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi

Distribution
Key media
www.reveniogroup.fi/en

Revenio Group in brief
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.

In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments


Revenio Group’s Financial statement release 2024 will be published on February 13, 2025

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Our team
  • Inderes som en investering
  • Tjänster för börsbolag
Our platform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.

  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • inderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Följda bolag
    • Teamet

Sekretessinställningar

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.